Mechanism of Action of L-Ornithine L-Aspartate
L-ornithine L-aspartate (LOLA) lowers blood ammonia through two distinct metabolic pathways: ornithine activates hepatic urea synthesis via the urea cycle, while aspartate stimulates glutamine synthesis through glutamine synthetase, primarily in skeletal muscle and perivenous hepatocytes. 1
Dual Ammonia-Lowering Pathways
Hepatic Urea Cycle Activation
- L-ornithine serves as a direct substrate and intermediary in the urea cycle within periportal hepatocytes, where it enters the cycle to facilitate ammonia incorporation into urea. 1
- Ornithine activates carbamoyl phosphate synthetase 1 (CPS1), the rate-limiting enzyme of the urea cycle, thereby enhancing the conversion of ammonia and bicarbonate into carbamoyl phosphate—the first committed step of urea synthesis. 1, 2
- This pathway is particularly important in residual functional hepatocytes in patients with cirrhosis, where hepatic urea synthesis capacity is compromised. 3
Glutamine Synthesis Pathway
- L-aspartate undergoes transamination to glutamate, which then serves as substrate for glutamine synthetase to incorporate ammonia into glutamine. 1
- This glutamine synthesis occurs in three key locations: perivenous hepatocytes, skeletal muscle, and brain tissue. 1
- Skeletal muscle becomes the primary site of ammonia detoxification in cirrhosis when hepatic function is impaired, making the muscle glutamine synthesis pathway critically important. 3
- The glutamine produced is subsequently excreted by the kidneys or further metabolized, effectively removing ammonia from systemic circulation. 4
Cellular and Metabolic Distribution
- LOLA readily dissociates into its constituent amino acids (L-ornithine and L-aspartate) after administration, which are then absorbed by active transport mechanisms. 1
- Both amino acids are rapidly distributed to target tissues including liver, skeletal muscle, and brain, where they participate in ammonia-lowering reactions. 1
- The cellular location of these pathways—periportal hepatocytes for urea synthesis and perivenous hepatocytes plus muscle for glutamine synthesis—creates complementary mechanisms that work synergistically. 1
Additional Metabolic Effects
Mitochondrial Function
- LOLA restores mitochondrial membrane potential and maintains mitochondrial integrity without inducing superoxide production in hepatocytes. 2
- Ornithine selectively penetrates mitochondria through the ornithine transporter 1 (ORNT1), allowing direct modulation of mitochondrial function. 4, 5
- LOLA reduces cellular ATP and acetyl-CoA levels while favorably modulating master regulators of energy balance including AMPK-α and PGC1α. 2
Branched-Chain Amino Acid Metabolism
- LOLA increases expression of BCAA enzyme transcripts (BCAT2, BCKDHA, BCKDK), enhancing the catabolism of branched-chain amino acids that accumulate in liver disease. 2
- This effect addresses the metabolic dysregulation seen in non-alcoholic fatty liver disease and cirrhosis. 2
Hepatoprotective Actions
- LOLA supplies glutamine and glutathione precursors, providing anti-oxidative capacity that protects hepatocytes from oxidative stress. 6
- The compound modulates fatty acid metabolism by affecting genes related to fatty acid import (CD36, CPT1), synthesis (FASN, SCD1, ACC1), and regulation (SREBF1). 2
- These pleiotropic effects extend beyond simple ammonia lowering to include direct hepatoprotective and metabolic regulatory functions. 6, 7
Clinical Relevance of Mechanism
- The dual-pathway mechanism explains why LOLA is effective even in advanced cirrhosis, where hepatic function is severely compromised—muscle glutamine synthesis compensates when hepatic urea synthesis fails. 3
- Intravenous LOLA is required for acute hepatic encephalopathy because oral formulations are ineffective due to first-pass metabolism and insufficient bioavailability. 8, 9
- The mechanism also explains LOLA's beneficial effects on sarcopenia in cirrhosis: by lowering ammonia, it reduces ammonia-induced muscle protein breakdown and myostatin expression. 3